Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aspartate-rich protein 1 (DRICH1) is a protein-coding gene in humans, also referred to as C22orf43 or KB-208E9.1[3][9]. It encodes a protein with a high content of aspartate residues. The molecular function of DRICH1 is not well characterized; current evidence suggests only general protein binding activity (GO:0005515)[1][5]. There is no established evidence that DRICH1 functions as a classic therapeutic target such as a receptor, enzyme, transporter, or transcription factor, nor is there evidence implicating direct involvement in specific molecular pathways or drug interactions. DRICH1 is associated with certain disease states based on genetic studies, including childhood acute lymphocytic leukemia and distal chromosome 22q11.2 deletion syndrome[3]. However, there is no current evidence for its use as a biomarker or safety concerns related to modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aspartate-rich protein 1 (DRICH1).